Clindamycin
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Clindamycin | 150-600 mg PO TID or 600mg IV Q8H | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 425 | 10 | 2-4 | 3-5 | 60-95 | 0.6-1.2 | N/A | 0 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Cimino, J. E., & Tierno, P. M. (1969). Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin). Applied microbiology, 17(3), 446-8. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=377709&tool=pmcentrez&rendertype=abstract
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB01190
- Eastwood, J. B., & Sc, B. (1974). A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure. Postgraduate Medical Journal, (November), 710-712.
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Roberts A, Eastwood J, Gower P, Fenton C, Curtis J. Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects. European journal of clinical pharmacology 1978; 14(6), 435-9.